Pinaki Bose, Ph.D
Associate Professor, Departments of Biochemistry & Molecular Biology and Oncology
University of Calgary
Director, Tumour Biology and Translational Research, Ohlson Research Initiative
Arnie Charbonneau Cancer Institute
Calgary, AB
Dr. Pinaki Bose completed his Ph.D. with Dr. Karl Riabowol at the University of Calgary, investigating the role of the ING1 tumour suppressor protein in DNA damage signaling and apoptosis. After completing his Ph.D., Pinaki joined the Ohlson Research Initiative (ORI) as a postdoctoral fellow and trained in the molecular epidemiology of head and neck cancers under the supervision of Drs. Joseph Dort and Nigel Brockton. As part of a second postdoctoral fellowship, Pinaki trained at the BC Cancer Agency (BCCA) Genome Sciences Centre in cancer genomics and bioinformatics under one of the leading bioinformaticians in the world, Dr. Steven Jones. Pinaki was also a member of the personalized oncogenomics (POG) program at BC Cancer. The POG initiative administers genome-guided targeted therapies to recurrent/metastatic cancer patients.
Dr. Bose currently directs the translational research program within the ORI, a multidisciplinary head and neck cancer research initiative. The Bose lab investigates the biology of head and neck, brain and lung cancers focusing on the role of the immune system in carcinogenesis and progression.
Steven Yip MD, MSc, FRCPC
Medical Oncologist
Medical Lead, Precision Oncology and Experimental Therapeutics
Chair, Southern Alberta GU Tumour Group
Clinical Associate Professor
Department of Oncology, Cumming School of Medicine
Arthur Child Comprehensive Cancer Centre
Calgary, AB
Dr. Steven Yip is a Staff Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta. He is the Southern Alberta GU Tumour Group Chair, Medical Lead of Precision Oncology and Experimental Therapeutics (POET), and Southern Alberta Prostate Cancer Research Institute (APCaRI) Co-Chair. He is a Clinical Assistant Professor of Medicine at the University of Calgary. He has an academic focus on translational research, PSMA PET/CT imaging and novel radiopharmaceutical drug development in advanced prostate cancer. He completed his medical oncology clinical and translational research genitourinary fellowship, under the supervision of Dr. Kim Chi at BC Cancer. He received his MD at the University of Alberta and trained at the University of British Columbia and the University of Calgary. He has a Masters of Science in Health Research Methodology from McMaster University.
Key Publications:
Reimers MA, Yip SM (Co-First Authors), Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. Eur Urol. 2019. In Press.
Yip SM, Wells C, Moreira RB, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst S, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Soulieres D, Canil CM, Kapoor A, Fu SY, Choueiri TK, Heng DYC. Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma Patients (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Cancer. 2018;124(18):3677-83.
Herberts C, Murtha AJ, Fu S, Wang G, Schönlau E, Xue H, Lin D, Gleave A,Yip SM, Angeles A, Hotte S, Tran B, North S, Taavitsainen S, Beja K, Vandekerkhove G, Ritch E, Warner E, Saad F, Iqbal N, Nykter Matti, Gleave ME, Wang Y, Annala M, Chi KN, and Wyatt AW. Activating AKT1 and PIK3CA mutation in metastatic castration-resistant prostate cancer. Eur Urol. 2020. https://doi.org/10.1016/j.eururo.2020.04.058
Jette N, Kumar M, Radhamani S, Arthur G, Goutam S, Yip SM, Kolinsky M, Williams G,
Bose P, Lees-Miller S. ATM-deficient cancers provide new opportunities for precision oncology. Cancers. Cancers (Basel). 2020 Mar 14;12(3). pii: E687. doi: 10.3390/cancers12030687
Yip SM, Loewen SK, Li H, Hao D, Easaw JC. Management of Medical Oncology Services in Canada: Redefined Workload with a Novel Supply-and-Demand Workforce Projection Model. J Oncol Pract. 2018;14(7):e438-e445.
Yip SM, Kaiser J, Li H, North S, Heng DY, Alimohamed NS. Real World Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio. Clin Genitourin Cancer. 2018;16(3):e637-e644.
Yip SM, Ruiz Morales J, Donskov F, Fraccon A, Umberto B, Rini BI, Lee JL, Bjarnason G, Sim HW, Beuselinck B, Kanesvaran R, Brugarolas J, Koutsoukos K, Fu SYF, Yuasa T, Davis I, Alva A, Kollmannsberger C, Choueiri TK, Heng DYC. Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer J.2017;1(1):41-47.
2025 POET CONGRESS FACULTY
2025 faculty coming soon….
